Sanders Morris Harris LLC Purchases 4,000 Shares of Johnson & Johnson $JNJ

Sanders Morris Harris LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 135.8% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 6,945 shares of the company’s stock after buying an additional 4,000 shares during the period. Sanders Morris Harris LLC’s holdings in Johnson & Johnson were worth $1,288,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Evolution Wealth Management Inc. bought a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $27,000. Semmax Financial Advisors Inc. raised its position in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares during the last quarter. GFG Capital LLC bought a new position in shares of Johnson & Johnson during the second quarter worth $35,000. 1248 Management LLC purchased a new position in Johnson & Johnson during the first quarter valued at $48,000. Finally, Vermillion & White Wealth Management Group LLC increased its holdings in Johnson & Johnson by 66.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after acquiring an additional 150 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $210.50 on Thursday. The stock has a 50 day moving average price of $197.44 and a 200-day moving average price of $178.46. Johnson & Johnson has a one year low of $140.68 and a one year high of $215.18. The stock has a market cap of $507.14 billion, a price-to-earnings ratio of 20.32, a price-to-earnings-growth ratio of 2.27 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 22nd. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Bank of America lifted their price objective on Johnson & Johnson from $204.00 to $220.00 and gave the stock a “neutral” rating in a research note on Monday. Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Finally, Royal Bank Of Canada set a $240.00 price target on shares of Johnson & Johnson in a research report on Wednesday. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $208.85.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.